SCHEMBL27420538

SCHEMBL27420538

COc1ccc(-n2nc(-n3c(C)ccc3C)cc2I)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.47
▸ PTGS1 P23219 3/20 0.42
▸ PTGS2 P35354 3/20 0.42
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ ATM Q13315 1/20 0.38
▸ MAPT P10636 4/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ HTT P42858 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ APEX1 P27695 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ MITF O75030 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27420552 0.86 LMNA (0.50) LMNAPTGS1PTGS2MEN1KMT2A
SCHEMBL26134738 0.82 LMNA (0.47) LMNAPTGS1PTGS2MEN1KMT2A
SCHEMBL14814435 0.82 POLB (0.42) PTGS1PTGS2MEN1KMT2AKDM4E
SCHEMBL14814216 0.82 MAPK1 (0.39) LMNAPTGS1PTGS2MEN1KMT2A
SCHEMBL21051309 0.80 LMNA (0.66) LMNAPTGS1PTGS2MEN1KMT2A
SCHEMBL27420557 0.75 LMNA (0.55) LMNAPTGS1PTGS2MEN1KMT2A
SCHEMBL14813999 0.72 NOTUM (0.42) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL8924910 0.71 NPC1 (0.53) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL26447250 0.71 ABCB11 (0.44) LMNAPTGS1PTGS2TSHRKDM4E
SCHEMBL6174608 0.69 LMNA (0.70) LMNAPTGS1PTGS2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085082-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2026-03-26 — — US disclosed
EP-4637760-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2025-10-29 — — EP disclosed
WO-2024137358-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2024-06-27 — — WO disclosed
WO-2024137358-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2024-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085082-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM5C LMNA 597/4885PTGS1 2685/4885PTGS2 3527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback